SynCo Bio provides GMP services to US firm
SynCo Bio Partners, a Dutch GMP contract manufacturer, has agreed two commercial contracts with an undisclosed US biopharmaceutical company.
SynCo Bio Partners, a Dutch GMP contract manufacturer, has agreed two commercial contracts with an undisclosed US biopharmaceutical company. Under the contract, SynCo will provide process validation and GMP commercial manufacturing services to support the launch of two biopharmaceutical products in the US.
SynCo has begun preparations for the manufacture of conformance lots in advance of its client's BLA filings, expected in late 2010. Commercial manufacturing is expected to start in 2011.
The products are both recombinant proteins, to be produced in E. coli and manufactured at SynCo's large-scale GMP facility in Amsterdam.
SynCo has previously supported process development efforts for both products.
Pierre Warffemius, ceo of SynCo Bio Partners said: "SynCo has grown steadily over the last ten years in a very competitive market. The foundation of this growth has been our ability to form strong and mutually beneficial relationships with our clients."
